Original articleKisspeptin and kisspeptin receptor immunoreactivity in euploid and aneuploid choriodecidual tissues of recurrent pregnancy losses
Section snippets
Patient Selection and Tissue Procurement
After obtaining approval from the local research ethics board (The University of British Columbia Clinical Research Ethics Board; REB number, H16-02334), using an already existing REDCap database of patients attending the RPL clinic at BC Women’s Hospital, Vancouver, British Columbia, Canada, 20 patients were randomly selected from 2 groups of patients with RPL: UE RPL and RPL due to AnE (10 patients from each group). An additional 10 cases of EAb were randomly selected from an archived tissue
Patients’ Characteristics
There was no statistically significant difference in the maternal and gestational ages at the time of abortion or pregnancy loss among the 3 groups (Table 1). In addition, there was no statistically significant difference in ethnicity, (P = .37), sex of the fetus (P = .16), or body mass index (P = .71) between patients with UE RPL and those with RPL due to AnE. The type and frequencies of chromosomal abnormalities in the AnE group are shown in Table 2.
Kisspeptin and KISS1R Immunoreactivity in Chorionic Tissues
On microscopic examination of chorionic
Discussion
Implantation and early placentation are complex processes that require synchronization between the maternal interface, the decidua, and the developing embryo (25). Recurrent pregnancy loss, particularly of unknown etiology, is considered a manifestation of imperfect implantation and/or placentation, and the exact molecular basis is still an area of ongoing research. In this study, we present, to our knowledge, the first assessment of KISS1 and KISS1R in the placenta of patients with RPL due to
Acknowledgment
This research was funded by University of British Columbia internal fund, Faculty of Medicine, Department of Obstetrics and Gynaecology and by the Missions office, Ministry of Higher education, Egypt.
References (34)
- et al.
The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54
J Biol Chem
(2001) - et al.
Analysis of the expression of neurokinin B, kisspeptin, and their cognate receptors NK3R and KISS1R in the human female genital tract
Fertil Steril
(2012) - et al.
Expression of metastin and a G-protein-coupled receptor (AXOR12) in epithelial ovarian cancer
Eur J Cancer
(2007) - et al.
Tumor suppressor role of KiSS-1 in bladder cancer: loss of KiSS-1 expression is associated with bladder cancer progression and clinical outcome
Am J Pathol
(2003) - et al.
Expression of kisspeptin/GPR54 and PIBF/PR in the first trimester trophoblast and decidua of women with recurrent spontaneous abortion
Pathol Res Pract
(2014) - et al.
HOXA10 expression in ectopic endometrial tissue
Fertil Steril
(2006) - et al.
Regulation of the expression of Th17 cells and regulatory T cells by IL-27 in patients with unexplained early recurrent miscarriage
J Reprod Immunol
(2013) - et al.
Depression and emotional stress is highly prevalent among women with recurrent pregnancy loss
Hum Reprod
(2015) - et al.
Increased cardiovascular disease risk in women with a history of recurrent miscarriage
Acta Obstet Gynecol Scand
(2018) - et al.
Recurrent pregnancy loss: a risk factor for long-term maternal atherosclerotic morbidity?
Am J Obstet Gynecol
(2014)
ESHRE guideline: recurrent pregnancy loss
Hum Reprod Open
Definitions of infertility and recurrent pregnancy loss: a committee opinion
Fertil Steril
Evaluation and treatment of recurrent pregnancy loss: a committee opinion
Fertil Steril
Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor
Nature
KiSS-1, a novel human malignant melanoma metastasis-suppressor gene
J Natl Cancer Inst
Downregulation of KiSS-1 expression is responsible for tumor invasion and worse prognosis in gastric carcinoma
Int J Cancer
Cited by (3)
KISS1 Gene Variations and Susceptibility to Idiopathic Recurrent Pregnancy Loss
2023, Reproductive Sciences
A.O.A. has nothing to disclose. S.M.G. has nothing to disclose. F.F.A. has nothing to disclose. J.T. has nothing to disclose. M.A.B. reports fees from AbbVie and Baxter.